MORGAN STANLEY PLC/CALL/ABBVIE/250/0.1/19.09.25 Share Price

Warrant

DE000ME85ZB8

Market Closed - Börse Stuttgart 09:16:07 17/05/2024 pm IST
0.169 EUR +3.05% Intraday chart for MORGAN STANLEY PLC/CALL/ABBVIE/250/0.1/19.09.25
Current month-7.14%
1 month-23.18%
Date Price Change
17/24/17 0.169 +3.05%
16/24/16 0.164 -0.61%
15/24/15 0.165 +1.85%
14/24/14 0.162 +2.53%
13/24/13 0.158 -0.63%

Delayed Quote Börse Stuttgart

Last update May 17, 2024 at 09:16 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
Issuer Morgan Stanley
WKN ME85ZB
ISINDE000ME85ZB8
Date issued 05/02/2024
Strike 250 $
Maturity 19/09/2025 (489 Days)
Parity 10 : 1
Emission price 0.14
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.44
Lowest since issue 0.147
Delta0.1x
Omega 8.588
Premium51.36x
Gearing88.23x
Moneyness 0.6657
Difference Strike 83.58 $
Difference Strike %+33.43%
Spread 0.007
Spread %3.95%
Theoretical value 0.1735
Implied Volatility 23.54 %
Total Loss Probability 93.90 %
Intrinsic value 0.000000
Present value 0.1735
Break even 251.89 €
Theta-0.01x
Vega0.03x
Rho0.02x

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
166.4 USD
Average target price
182.3 USD
Spread / Average Target
+9.52%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW